N-substituted oxindoline derivatives as calcium channel blockers
A series of N-substituted oxindole derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.
1. A compound of structural formula I:
or pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof: wherein:
R 1 =aryl or heteroaryl, optionally substituted with 1-3 substituents consisting of: C 1-6 alkyl, C 1-4 -fluoroalkyl, C 6-10 -aryl, or C 6-10 heteroaryl, F, Cl, Br, CN, OR 5 , NR 5 R 6 , SO 2 R 5 , SO 2 NR 5 R 6 , NR 5 SO 2 R 6 , CO 2 R 5 , CONR 5 R 6 ;
R 2 =C 1-6 alkyl, C 1-6 fluoroalkyl;
R 3 =(CH 2 ) n aryl or (CH 2 ) n heteroaryl, wherein each aryl or heteroaryl is optionally substituted with 1-3 substituents consisting of: C 1-6 alkyl, C 1-4 -fluoroalkyl, C 6-10 -aryl, C 6-10 heteroaryl, F, Cl, Br, CN, OR 5 , NR 5 R 6 , SO 2 R 5 , SO 2 NR 5 R 6 , NR 5 SO 2 R 6 , CO 2 R 5 , CONR 5 R 6 ;
each R 4 is independently selected from H, C 1-6 alkyl, C 1-4 -fluoroalkyl, aryl, heteroaryl, F, Cl, Br, CN, OR 5 , NR 5 R 6 , SO 2 R 5 , SO 2 NR 5 R 6 , NR 5 SO 2 R 6 , CO 2 R 5 , and CONR 5 R 6 ;
R 5 and R 6 are each independently selected from H, C 1-6 alkyl, C 1-4 -fluoroalkyl, C 3-7 -cycloalkyl, C 6-10 -aryl, and C 6-10 heteroaryl or R 5 and R 6 join to form a 3-7 member carbocyclic or heterocyclic ring and
n=0-6.
2. The compound according to claim 1 wherein R 2 is methyl, and R 3 is a methylene-linked aryl or heteroaryl.
3. The compound according to claim 1 represented by:
wherein the stereocenter depicted by “*” in formula I is in the S or R stereochemical configuration.
4. The compound according to claim 1 wherein R 1 is an aryl optionally substituted.
5. The compound according to claim 3 represented by structural formula Ib
wherein R 3 is a methylene-linked aryl or heteroaryl substituent and the stereocenter depicted by “*” in formula Ib is in the R stereochemical configuration and Ar is selected from the group consisting of phenyl, napthyl, and biphenyl.
6. The compound according to claim 5 wherein R 3 is selected from the group consisting of a methylene-linked phenyl, napthyl, tetrahydronapthyl, indanyl, biphenyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isoquinolinyl, morpholinyl, oxazolyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, and quinolinyl.
7. The compound according to claim 3 wherein R 1 is a heteroaryl, optionally substituted.
8. The compound according to claim 7 represented by structural formula Ic
wherein R 3 is a methylene-linked aryl or heteroaryl and the stereocenter depicted by “*” in formula Ic is in the R stereochemical configuration and Het is selected from the group consisting of thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazoiyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, triazolyl, oxazolyl, thiazolyl, and isoxazoyl.
9. The compound according claim 8 wherein R 3 is selected from the group consisting of methylene-linked phenyl, napthyl, tetrahydronapthyl, indanyl, biphenyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isoquinolinyl, morpholinyl, oxazolyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, and quinolinyl.
10. The compound according to claim 1 wherein R 1 is heteroaryl and R 3 is a methylene-linked heteroaryl.
11. The compound according to claim 10 wherein the heteroaryl is selected from the group consisting of thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazoiyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, triazolyl, oxazolyl, thiazolyl, and isoxazoyl and for R 3 n is 1 and the heteroaryl is selected from the group consisting of furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isoquinolinyl, morpholinyl, oxazolyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, and quinolinyl.
12. A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1 .
13. A compound which is:
3-methyl-1-pyridin-2-yl-3-(pyrimidin-5-ylmethyl)-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
5-(4-fluorophenyl)-3-methyl-1-pyridin-2-yl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
1-(6-aminopyrazin-2-yl)-5-(3-chloro-4-fluorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
3-methyl-1-pyrazin-2-yl-3-(pyrimidin-5-ylmethyl)-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
1-(5-aminopyrazin-2-yl)-5-(3-chlorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-methyl-1-pyrimidin-2-yl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-methyl-1-pyridin-4-yl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
1-(5-aminopyrazin-2-yl)-5-(3-chloro-4-fluorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-1-(1H-imidazol-4-yl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-methyl-1-pyridin-3-yl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
3-methyl-3-(pyrimidin-5-ylmethyl)-1-(1H-1,2,4-triazol-3-yl)-5-[3-(2,2,2-trifluoroethoxy)-phenyl]-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1-(1H-1,2,4-triazol-3-yl)-1,3-dihydro-2H-indol-2-one,
5-(3,4-difluorophenyl)-3-methyl-1-pyrimidin-2-yl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
5-(4-fluorophenyl)-3-methyl-1-pyrimidin-2-yl-3-(pyrimidin-5-ylmethyl)-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-5-[4-fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-5-[4-fluoro-3-(trifluoromethyl)phenyl]-3-methyl-1-pyridin-2-yl-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-5-[2-fluoro-5-(trifluoromethyl)phenyl]-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-3-methyl-1-pyridin-2-yl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-3-methyl-1-pyrimidin-2-yl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyridin-2-yl-1,3-dihydro-2H-indol-2-one,
5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-1,3-dimethyl-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-3-methyl-1-pyrazin-2-yl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-1,3-dimethyl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2one,
1-(6-aminopyridin-2-yl)-5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1,3-dihydro-2H-indol-2-one,
1-(5-aminopyrazin-2-yl)-5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1,3-dihydro-2H-indol-2-one,
5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyridin-2-yl-1,3-dihydro-2H-indol-2-one,
5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyrazin-2-yl-1,3-dihydro-2H-indol-2-one,
5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-1-(6-methoxypyridin-2-yl)-3-methyl-1,3-dihydro-2H-indol-2-one,
5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-1-(1H-imidazol-4-yl)-3-methyl-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyridin-2-yl-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-3-methyl-1-(1H-1,2,4-triazol-5-yl)-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-3-methyl-1-pyridin-3-yl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-3-methyl-1-pyrimidin-5-yl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
1-(5-aminopyridin-2-yl)-3-(3,5-difluorobenzyl)-3-methyl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-3-methyl-1-pyridin-4-yl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
1-(6-aminopyrazin-2-yl)-3-(3,5-difluorobenzyl)-3-methyl-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-indol-2-one,
1-(6-aminopyridin-2-yl)-5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1,3-dihydro-2H-indol-2-one,
1-(6-aminopyrazin-2-yl)-5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1,3-dihydro-2H-indol-2-one,
1-(5-aminopyrazin-2-yl)-5-(3-chlorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-5-(4-fluorophenyl)-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
1-(6-aminopyrazin-2-yl)-3-(3,5-difluorobenzyl)-5-(4-fluorophenyl)-3-methyl-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-5-(3,4-difluorophenyl)-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
1-(5-aminopyrazin-2-yl)-5-(3-chloro-4-fluorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-(3,5-difluorobenzyl)-1-(1H-imidazol-4-yl)-3-methyl-1,3-dihydro-2H-indol-2-one,
5-(3-chloro-4-fluorophenyl)-3-(3,5-difluorobenzyl)-3-methyl-1-pyridin-4-yl-1,3-dihydro-2H-indol-2-one,
3-(3,5-difluorobenzyl)-5-(3,4-difluorophenyl)-3-methyl-1-pyrimidin-2-yl-1,3-dihydro-2H-indol-2-one,
3-methyl-3-pyrimidin-5-ylmethyl-1-(1H-[1,2,4]triazol-3-yl)-5-(3-trifluoromethoxy-phenyl)-1,3-dihydro-indol-2-one,
3-methyl-1-(1-methyl-1H-imidazol-4-yl)-3-pyrimidin-5-ylmethyl-5-(3-trifluoromethoxy-phenyl)-1,3-dihydro-indol-2-one,
5-(3,4-difluoro-phenyl)-3-methyl-1-(1-methyl-1H-imidazol-4-yl)-3-pyrimidin-5-ylmethyl-1,3-dihydro-indol-2-one,
5-(3,4-difluoro-phenyl)-3-methyl-3-pyrimidin-5-ylmethyl-1-(1H-1,2,4-triazol-3-yl)-1,3-dihydro-indol-2-one,
3-methyl-3-pyrimidin-5-ylmethyl-1-(1H-1,2,4-triazol-3-yl)-5-[3-(2,2,2-trifluoro-ethoxy)-phenyl]-1,3-dihydro-indol-2-one,
3-methyl-1-(1-methyl-1H-imidazol-4-yl)-3-pyrimidin-5-ylmethyl-5-[3-(2,2,2-trifluoro-ethoxy)-phenyl]-1,3-dihydro-indol-2-one,
or
pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
14. A method for treating chronic or acute pain in a mammalian patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
15. A method for treating epilepsy in a mammalian patient in need thereof, which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.